MannKind reported $41.03M in Trade Debtors for its fiscal quarter ending in September of 2026.





Trade Debtors Change Date
Adma Biologics USD 138.23M 2.37M Jun/2026
BioCryst Pharmaceuticals USD 110.76M 3.94M Jun/2026
Eli Lilly USD 23.48B 2.3B Jun/2026
Halozyme Therapeutics USD 518.59M 65.26M Sep/2026
Insmed USD 259.27M 43.94M Sep/2026
Karyopharm Therapeutics USD 23.36M 2.82M Mar/2026
MacroGenics USD 144.17M 133.75M Jun/2026
MannKind USD 41.03M 2.17M Sep/2026
Merck USD 12.56B 354M Jun/2026
Novavax USD 106.45M 72.27M Dec/2025
Novo Nordisk DKK 17.56B 82.7B Jun/2026
Pfizer USD 17.57B 1.38B Sep/2026
Sanofi EUR 326M 166M Sep/2026
Xencor USD 42.23M 30.23M Jun/2026